Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors
Sklavenitis-Pistofidis, R.; Lightbody, E. D.; Reidy, M.; Tsuji, J.; Aranha, M. P.; Heilpern-Mallory, D.; Huynh, D.; Chong, S. J. F.; Hackett, L.; Haradhvala, N. J.; Wu, T.; Su, N. K.; Berrios, B.; Alberge, J.-B.; Dutta, A.; Davids, M. S.; Papaioannou, M.; Getz, G.; Ghobrial, I. M.; Manier, S.
Show abstract
The development of targeted therapy for patients with Multiple Myeloma (MM) is hampered by the low frequency of actionable genetic abnormalities. Gain or amplification of chr1q (Amp1q) is the most frequent arm-level copy number gain in patients with MM, and it is associated with higher risk of progression and death despite recent advances in therapeutics. Thus, developing targeted therapy for patients with MM and Amp1q stands to benefit a large portion of patients in need of more effective management. Here, we employed large-scale dependency screens and drug screens to systematically characterize the therapeutic vulnerabilities of MM with Amp1q and showed increased sensitivity to the combination of MCL1 and PI3K inhibitors. Using single-cell RNA sequencing, we compared subclones with and without Amp1q within the same patient tumors and showed that Amp1q is associated with higher levels of MCL1 and the PI3K pathway. Furthermore, by isolating isogenic clones with different copy number for part of the chr1q arm, we showed increased sensitivity to MCL1 and PI3K inhibitors with arm-level gain. Lastly, we demonstrated synergy between MCL1 and PI3K inhibitors and dissected their mechanism of action in MM with Amp1q.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Genetic Subtypes of Smoldering Multiple Myeloma are associated with Distinct Pathogenic Phenotypes and Clinical Outcomes 97%
- Aberrant non-canonical NF-kappaB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma 96%
- Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma 96%
Similar papers in this journal
- Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm 94%
- Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL 93%
- Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival 92%
Similar papers in this journal
- Systems medicine dissection of chromosome 1q amplification reveals oncogenic regulatory circuits and informs targeted therapy in cancer 96%
- Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells 95%
- Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of Diffuse Large B Cell Lymphoma 94%
Similar papers in this journal
- Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia 93%
- Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in mediating targeted therapy dosage challenges 93%
- Precision combination therapies based on recurrent oncogenic co-alterations 93%
Similar papers in this journal
- A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma 96%
- DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression 94%
- Clinical interpretation of integrative molecular profiles to guide precision cancer medicine 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.